Trial Profile

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apalutamide (Primary) ; Gonadotropin releasing hormone
Indications Adenocarcinoma; Prostate cancer
Focus Registrational; Therapeutic Use
Acronyms TITAN
Sponsors Aragon Pharmaceuticals; Janssen Research & Development; Janssen-Cilag

Most Recent Events

20 Mar 2026 According to Clinical Trials Information System record, the trail has been completed in Spain.
21 Oct 2024 Planned End Date changed from 1 Sep 2025 to 31 Dec 2027.
25 Jul 2024 Planned End Date changed from 5 Sep 2024 to 1 Sep 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com